# Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

> **NCT03579966** · PHASE3 · TERMINATED · sponsor: **Catalyst Pharmaceuticals, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Myasthenia Gravis, MuSK
- AChR Myasthenia Gravis

## Interventions

- **DRUG:** Amifampridine Phosphate

## Key facts

- **NCT ID:** NCT03579966
- **Lead sponsor:** Catalyst Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-11
- **Primary completion:** 2022-08-05
- **Final completion:** 2022-08-05
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** Lack of measure appropriate data (MG-ADL).
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579966, "Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03579966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*